Astellas Pharma v. Apsen Farmacêutica — Appeal Dismissed, Suspension Upheld
Astellas Pharma, Inc. brought an infringement action against Brazilian generics firm Apsen Farmacêutica S/A over two pharmaceutical patents covering an alpha-crystal acetanilide compound and a modified-release oral composition. The Court of Justice of São Paulo dismissed Apsen’s appeal in February 2024, maintaining the procedural suspension that protects Astellas’s jurisdictional position.
São Paulo court upholds suspension in Astellas pharma patent dispute
Astellas Pharma, Inc., the Tokyo-headquartered originator pharmaceutical company, filed an infringement action before the Court of Justice of São Paulo (Case No. 2332814-55.2023.8.26.0000) against Apsen Farmacêutica S/A, a Brazilian generics and branded-generics manufacturer. The dispute centres on two Brazilian granted patents: BRPI0919466B1, covering an alpha-crystal form of an acetanilide compound and solid pharmaceutical compositions containing it, and BRPI0213570B1, directed to a modified-release oral pharmaceutical composition and its manufacturing process.
The case reached the Court of Justice of São Paulo on appeal, where Apsen challenged a procedural suspension order. The appellate panel dismissed Apsen’s appeal as unfounded in a decision closed on 23 February 2024. The court held that the suspension was necessary to safeguard the effectiveness of the jurisdictional provision and to preserve the logical rationality of judicial decisions — standard Brazilian appellate language indicating the lower court’s protective order was correctly granted and appropriately maintained pending the underlying merits proceeding.
The appeal dismissal does not resolve the underlying infringement merits; it confirms that the suspension — likely a preliminary injunction or stay — remains operative, giving Astellas continued procedural protection. What drove Apsen to seek lifting of the suspension is not specified in the available public record, nor is the quantum of any damages claim. The speed with which the appellate panel disposed of the challenge, characterising it as unfounded, suggests the lower court’s reasoning was found to be well-grounded and unlikely to be disturbed on the available record.
Filing to dismissal in 0 days
Case closed 23 February 2024 — duration not recorded in public filing
What the appeal dismissal means for each party
Appeal dismissed as unfounded — what that means in Brazilian procedure
Under Brazilian civil procedure, dismissing an appeal as ‘unfounded’ (improcedente) means the appellate panel found no legal or factual basis to disturb the lower court’s decision. For Apsen, this closes the avenue to lift the suspension through this appeal. The court’s language — preserving ‘logical rationality of judicial decisions’ — signals deference to the lower court’s reasoning and a high threshold for interference at this stage.
Procedural defeat for ApsenThe suspension stays in place — and why that matters commercially
The maintained suspension likely operates as a stay or interim injunction preventing Apsen from commercialising the infringing product or process while the merits are determined. For Astellas, this is a meaningful interim win: it preserves market exclusivity protection during potentially lengthy Brazilian patent litigation. For Apsen, it restricts commercial freedom on the relevant product line until the underlying case is resolved or a higher court intervenes.
Astellas retains interim protectionTwo distinct patent families — crystal form and formulation both in dispute
The assertion of both BRPI0919466B1 (alpha-crystal acetanilide form) and BRPI0213570B1 (modified-release oral composition and process) is a layered enforcement strategy typical of originator pharma companies. Stacking a polymorphic crystal patent with a formulation/process patent is designed to create multiple independent barriers to generic entry, making design-arounds more complex and expensive for competitors.
Stacked patent enforcementThe underlying infringement claim remains unresolved
The February 2024 appellate ruling addresses only the suspension challenge — not the substantive question of whether Apsen infringes either patent. The merits of the infringement action are expected to continue before the lower Brazilian court. Parties monitoring this dispute should track the main proceeding separately, as a final infringement ruling could carry damages, injunctive relief, or a finding of invalidity if Apsen raises a counterclaim.
Merits proceeding ongoingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Astellas Pharma, Inc. | Company | Originator pharmaceutical company — holder of BRPI0919466B1 and BRPI0213570B1Search in Eureka ↗ |
| Defendant | Apsen Farmacêutica S/A | Company | Apsen Farmacêutica S/A — Brazilian generics and branded-generics manufacturerSearch in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | Court of Justice of Sao Paulo — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The court’s language — that the suspension ‘safeguards the effectiveness of the jurisdictional provision and the logical rationality of judicial decisions’ — is a formulaic but substantive Brazilian appellate formulation. It indicates the panel found the lower court’s grant of suspension was both legally grounded and procedurally rational. Dismissing the appeal ‘as unfounded’ is the strongest available rebuff: no partial relief, no remand. For Astellas, the ruling preserves all interim protections. For Apsen, the appellate route to lift the suspension is now closed absent a further escalation or a change in circumstances at the merits level.
BRPI0919466B1 & BRPI0213570B1 — pharmaceutical crystal form and modified-release composition
BRPI0919466B1 protects a specific alpha-crystal polymorph of an acetanilide-derived compound and solid pharmaceutical compositions incorporating it. Polymorph patents are strategically significant because they can extend effective market exclusivity beyond a compound’s original patent expiry — a generic manufacturer must replicate the specific crystal form or find a non-infringing alternative. BRPI0213570B1 covers a modified-release oral pharmaceutical composition and the process for making it, adding a formulation-layer barrier independent of the crystal-form claims. Both patents are granted in Brazil under the BRPI numbering system, indicating applications of international origin entered the Brazilian national phase.
The combination of a crystal-form patent and a formulation/process patent targeting the same therapeutic product is a well-documented originator strategy in pharmaceutical IP. Together, these patents can block generic market entry on two independent legal bases, forcing a challenger to either design around both or mount validity challenges on each. For competitors in the acetanilide compound or modified-release oral formulation space operating in Brazil, these patents represent material FTO risk. Any product launch in this therapeutic class in Brazil should be preceded by a careful claim-by-claim analysis of both BRPI0919466B1 and BRPI0213570B1.
Should you run an FTO against BRPI0919466B1 and BRPI0213570B1?
Any pharmaceutical company — originator, generic, or biosimilar — developing or commercialising an acetanilide-derived compound in alpha-crystal form, or a modified-release oral formulation in Brazil, should treat these two patents as priority FTO targets. The ongoing litigation and the upheld suspension confirm that Astellas is actively enforcing these rights. A product entering the Brazilian market in this space without a cleared FTO opinion faces real interim-injunction risk, as this case demonstrates courts are willing to maintain suspensions while proceedings are ongoing.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of BRPI0919466B1 and BRPI0213570B1 against your product’s technical profile in minutes — identifying which claims pose the greatest infringement risk and surfacing relevant prior art that could support a validity challenge. Eureka’s claim monitoring feature can also alert your team if Astellas files continuation or divisional applications in Brazil that extend coverage into related formulation or process territory, keeping your IP risk assessment current throughout the product lifecycle.
Run a freedom-to-operate analysis on BRPI0919466B1 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical patent infringement cases in Brazil and LATAM
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for pharmaceutical patent enforcement in Brazil
Brazil’s appellate courts are willing to maintain interim protective orders in pharmaceutical patent disputes, creating meaningful interim leverage for originator companies.
Brazilian courts actively protect originator pharmaceutical patents at interim stage
The Court of Justice of São Paulo’s swift rejection of Apsen’s appeal confirms that Brazilian appellate courts will uphold procedural suspensions designed to protect patent holders during litigation. Originator companies facing generic entry should consider seeking equivalent protective orders early in Brazilian proceedings, as courts appear receptive to maintaining them.
Stacking crystal-form and formulation patents strengthens enforcement position
Astellas’s dual-patent strategy — asserting both a polymorphic crystal patent and a modified-release formulation patent — is a recognised approach to multiplying barriers to generic entry. Companies in the pharmaceutical space should audit whether their own portfolios include complementary patent pairs that can be asserted in tandem to reinforce exclusivity.
Astellas v Apsen — key questions answered
The Court of Justice of São Paulo dismissed Apsen Farmacêutica’s appeal as unfounded on 23 February 2024, maintaining the procedural suspension that protects Astellas’s position in the underlying infringement action. The appeal ruling does not resolve the infringement merits, which remain before the lower court.
Astellas asserted two Brazilian granted patents: BRPI0919466B1, covering an alpha-crystal form of an acetanilide compound and solid pharmaceutical compositions, and BRPI0213570B1, directed to a modified-release oral pharmaceutical composition and its manufacturing process. Both are enforcement-active patents in the Brazilian market.
The ruling confirms that Brazilian appellate courts will uphold interim suspension orders in pharmaceutical patent disputes when the lower court’s reasoning is sound. Generic companies seeking to challenge such suspensions face a high appellate threshold. Early FTO analysis and validity assessments before product launch are critical to managing this risk in Brazil.
No. The February 2024 decision only resolved Apsen’s appeal against the procedural suspension. The substantive infringement merits — whether Apsen’s products infringe BRPI0919466B1 and BRPI0213570B1 — remain to be determined in the primary proceedings before the Brazilian court of first instance.
A polymorph patent protects a specific crystal form of a chemical compound. BRPI0919466B1 claims the alpha-crystal form of an acetanilide-derived compound. Such patents are strategically significant because they can maintain market exclusivity even after a compound’s base patent expires — a generic must use the same crystal form or invest in a design-around, adding cost and regulatory complexity to market entry.
PatSnap Eureka searches patents and litigation data to answer instantly.